Efficacy and Safety Profile of SGLT-2 Inhibitors as Add-on Therapy in Patients with Type 2 Diabetes: A Comprehensive Review

This study was conducted to evaluate the efficacy and safety profile of Sodium-glucose co-transporter 2 SGLT-2 inhibitors as adjunctive therapy in patients with Type 2 diabetes. The aim was to assess their therapeutic benefits and potential risks when used in combination with st...

Full description

Saved in:

Bibliographic Details
Main Authors:	Syed Afzal Uddin Biyabani, Neelkantreddy Patil, Syed Raziuddin Faisal
Format:	Article
Language:	English
Published:	Rajiv Gandhi University of Health Sciences 2024-01-01
Series:	RGUHS Journal of Pharmaceutical Sciences
Online Access:	https://journalgrid.com/view/article/rjps/12434275
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01)

First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety
by: Hany Ahmed Muhammed Khalil, et al.
Published: (2025-01-01)

EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
by: Ramazan Çakmak, et al.
Published: (2025-01-01)

Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient
by: David S. H. Bell
Published: (2015-01-01)

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
by: Maria Mirabelli, et al.
Published: (2019-01-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
by: Nazif Yalçın, et al.
Published: (2025-04-01)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
by: Mohamed Alhemeiri, et al.
Published: (2022-01-01)

The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.
by: Yongin Cho, et al.
Published: (2025-01-01)

Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials
by: Ali Ibrahim Rahil, et al.
Published: (2025-05-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Osteomyelitis Pubis After Initiation of an SGLT2 Inhibitor
by: Adriana Nadeau, et al.
Published: (2022-10-01)

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis
by: Chung-Shu Lee, et al.
Published: (2025-05-01)

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients
by: Syed Hamza Haider, et al.
Published: (2025-06-01)

The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients
by: Jia-Yuh Sheu, et al.
Published: (2024-11-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)
by: Hae Jin Kim, et al.
Published: (2024-01-01)

SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes
by: Qian Wu, et al.
Published: (2025-06-01)

Safety and efficacy of SGLT2 inhibitors in heart failure patients with ischemic and non-ischemic etiologies: a systematic review and meta-analyses
by: Hasan Fareed Siddiqui, et al.
Published: (2025-03-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease
by: Dorota Wasko-Czopnik, et al.
Published: (2023-12-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
by: Kris Aubrey-Bassler, et al.
Published: (2019-02-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

A Review on the Relationship between SGLT2 Inhibitors and Cancer
by: Hao-Wen Lin, et al.
Published: (2014-01-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice—A Cross-Sectional Study
by: Liana Iordan, et al.
Published: (2024-12-01)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism
by: Brett W. Sperry, MD, et al.
Published: (2025-08-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis
by: Nikita Ermolaev, et al.
Published: (2025-03-01)

Is it Time to Expand the Use of SGLT2 Inhibitors in Kidney Transplant Recipients?
by: Kajaree Giri, et al.
Published: (2025-03-01)